SKAN Group Ltd

SKAN

Equity

ISIN CH0013396012 / Valor 1339601

SIX Swiss Exchange (2025-11-20)

CHF 46.40+2.59%

SKAN Group Ltd
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

SKAN Group Ltd is a company specializing in the development and support of isolators and related equipment, primarily serving industries that require stringent contamination control, such as pharmaceuticals and biotechnology. The company offers a range of services under its SKANalytix brand, focusing on data analysis, evaluation, and documentation to enhance the performance and compliance of isolators. These services include assessing the cleanability of isolators, developing tailored cleaning processes, and evaluating the impact of hydrogen peroxide on sterility tests. SKAN adheres to Good Manufacturing Practice (GMP) standards, ensuring high-quality service execution and documentation. To address the challenges posed by evolving user specifications, production changes, and regulatory updates, SKAN provides options for upgrading existing equipment, integrating the latest technologies to extend the lifespan and functionality of isolators. Additionally, SKAN offers a comprehensive LifeCycle Support portfolio, including a 24-hour emergency service hotline staffed by specialists to ensure minimal downtime and optimal operation of isolators.

Summarized from source with an LLMView SourceSector: Industrials

Order Intake Growth

SKAN Group Ltd's order intake surged by 20.2% to CHF 212.972 million in H1 2025 compared to the same period in 2024. This robust increase highlights strong demand and a solid order pipeline, positioning the company well for future growth.

Net Sales Decline

Net sales from goods and services decreased by 17.8% to CHF 134.568 million in the first half of 2025. The decline was primarily driven by project postponements in vaccine lines and a global shift in vaccine-related demand.

EBITDA Reduction

EBITDA experienced a significant drop of 95.7%, falling to CHF 928,000 in H1 2025. This decrease was attributed to ongoing investments in property, plant, and equipment, as well as the impact of project delays on profitability.

Strong Order Backlog

The order backlog reached a record CHF 386.392 million, a 21.4% increase from the end of 2024. This growth underscores the company's ability to secure long-term contracts and maintain a steady revenue stream.

Equity and Cash Flow

Equity decreased by 9.4% to CHF 183.430 million, with the equity ratio dropping to 48.1%. Meanwhile, cash flow from operating activities saw a notable increase, reinforcing the company's liquidity position despite challenges in sales and EBITDA.

Summarized from source with an LLMView Source

Key figures

-32.9%1Y

-26.8%3Y

%5Y

Performance

28.4%1Y

28.5%3Y

33.6%5Y

Volatility